# Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

> **NCT00301899** · PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 37 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** pertuzumab
- **BIOLOGICAL:** trastuzumab

## Key facts

- **NCT ID:** NCT00301899
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2012-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301899, "Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00301899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*